You can now read 5 articles in a month for free on BostonGlobe.com. Read as much as you want anywhere and anytime for just 99¢.

Mersana, Merck Serono announce new oncology partnership

Mersana Therapeutics Inc. and Merck Serono said Tuesday that they will collaborate on antibody-drug conjugates that can be used to develop potential cancer treatments.

Headquartered in Cambridge, Mersana is working on an antibody-drug conjugate platform that is designed for the delivery of drugs; these conjugates can be loaded with a drug payload that is released once inside a targeted cancer cell.

Continue reading below

With headquarters in Germany, Merck Serono is the biopharmaceutical division of Merck.

Under the agreement, Mersana will receive an upfront payment of an undisclosed amount. If Mersana achieves all the milestones in the agreement, the upfront and milestone payments could amount to as much as $792 million, the company said.

In July 2012, Mersana Therapeutics raised $27 million in Series A-1 financing. Investors include NEA, Fidelity Biosciences, Harris & Harris Group, Pfizer Venture Investments, ProQuest Investments, and Rho Ventures.

 In April, Mersana announced a collaboration with Takeda, a Japanese drug giant with a big presence in Massachusetts. That collaboration seeks to develop a type of antibody-drug conjugates that will use Takeda’s novel antibodies against multiple cancer targets.

Chris Reidy can be reached at reidy@globe.com.
Loading comments...
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com
Already a subscriber?
Your city. Your stories. Your Globe.
Yours FREE for two weeks.
Enjoy free unlimited access to Globe.com for the next two weeks.
Limited time only - No credit card required!
BostonGlobe.com complimentary digital access has been provided to you, without a subscription, for free starting today and ending in 14 days. After the free trial period, your free BostonGlobe.com digital access will stop immediately unless you sign up for BostonGlobe.com digital subscription. Current print and digital subscribers are not eligible for the free trial.
Thanks & Welcome to Globe.com
You now have unlimited access for the next two weeks.
BostonGlobe.com complimentary digital access has been provided to you, without a subscription, for free starting today and ending in 14 days. After the free trial period, your free BostonGlobe.com digital access will stop immediately unless you sign up for BostonGlobe.com digital subscription. Current print and digital subscribers are not eligible for the free trial.